Clinical Trial Update: Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given Intradermally [Phase 1]

View source ↗

Summary

Phase I open-label study evaluating a recombinant DNA vaccine encoding influenza A H5 hemagglutinin administered intradermally; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Influenza Virus Infection
• Influenza Virus Infection H5n1 Subtype

Drugs mentioned

• VRC-AVIDNA036-00-VP

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Influenza A Virus, H5N1 Subtype, Influenza A Virus | Phase 1 | Status: COMPLETED